| 126 | 0 | 37 |
| 下载次数 | 被引频次 | 阅读次数 |
通过梳理现代研究并结合临床实践，诠释络息成积理论与缝隙连接细胞间通讯的相关性及其在肿瘤防治中的理论内涵与临床应用。生理方面，缝隙连接与络脉在结构分布、物质交换、信息传递方面具有相关性。病理方面，缝隙连接介导代谢耦联失衡类似于络脉郁滞，为肿瘤发病之本；异型缝隙连接建立类似于络脉亢变，为肿瘤转移之因；缝隙连接蛋白翻译后修饰紊乱类似于络虚不荣，为肿瘤恶化之源。临床论治肿瘤当遵循“络息成积”的病机演变规律，初期解毒通络，恢复细胞间通讯功能以祛肿瘤新生；进展期平亢抑络，阻断异型缝隙连接建立以截肿瘤转移；终末期扶正通络，调节缝隙连接蛋白翻译后修饰以遏肿瘤病程。
Abstract：By reviewing modern research and integrating clinical practice, this paper elucidates the correlation between the traditional Chinese medicine theory of pathological accumulation from collateral obstruction and gap junction intercellular communication(GJIC), as well as its theoretical connotation and clinical application in tumor prevention and treatment. Physiologically, gap junction and collateral channels share similarities in structural distribution, substance exchange and information transmission. Pathologically, metabolic coupling mediated by dysfunctional gap junction resembles collaterals stagnation, forming the basis of tumor pathogenesis. The establishment of heterotypic gap junction parallels collateral hyperactivity, contributing to tumor metastasis. The post-translational modifications(PTMs) disorder of connexins is similar to the deficiency of collaterals, serving as a driver of tumor progression.Clinically, tumor treatment should follow the pathomechanism of collateral obstruction leading to pathological accumulation. In the early stage, detoxifying and unblocking collaterals can restore intercellular communication and inhibit tumorigenesis; in the progressive stage, calming hyperactivity and suppressing aberrant collateral pathways can prevent metastasis by interrupting heterotypic gap junction formation; and in the terminal stage, supporting vital qi and modulating PTMs of connexins can help delay tumor progression.
[1]XIAO Y, YU D. Tumor microenvironment as a therapeutic target in cancer[J]. Pharmacol Ther, 2021, 221:107753. doi:10. 1016/j. pharmthera. 2020. 107753.
[2]ZEFFERINO R, PICCOLI C, GIOIA SD, et al. Gap junction intercellular communication in the carcinogenesis hallmarks:is this a phenomenon or epiphenomenon?[J].Cells, 2019, 8(8):896.
[3]KUTOVA OM, POSPELOV AD, BALALAEVA IV. The multifaceted role of connexins in tumor microenvironment initiation and maintenance[J]. Biology(Basel), 2023, 12(2):204.
[4]常富业，王永炎.络病辨证浅析[J].北京中医药大学学报，2003,26(6):9-11.
[5]吴以岭.中医络病学说与三维立体网络系统[J].中医杂志，2003,44(6):407-409.
[6]王潇凡，张墨涵，林事成，等.基于络病理论从络息成积辨析甲状腺结节病机[J].世界中西医结合杂志，2023,18(7):1476-1479,1484.
[7]褚雪镭，谢飞宇，龙思丹，等.基于络病理论探析大肠癌肝转移的病机演变[J].世界中西医结合杂志，2022,17(10):1909-1912.
[8]ZHU Y. Gap junction-dependent and-independent functions of connexin43 in biology[J]. Biology(Basel), 2022,11(2):283.
[9]潘科华，丁一峰，舒飞，等.缝隙连接蛋白26与肿瘤关系的研究进展[J].赣南医科大学学报，2024,44(9):891-898.
[10]常成成，魏聪，吴以岭.脉络学说“孙络-微血管”概念及其临床指导意义[J].中医杂志，2016,57(1):7-11.
[11]LUCACIU SA, LEIGHTON SE, HAUSER A, et al.Diversity in connexin biology[J]. J Biol Chem, 2023,299(11):105263.
[12]ZHOU M, ZHENG M, ZHOU X, et al. The roles of connexins and gap junctions in the progression of cancer[J].Cell Commun Signal, 2023, 21(1):8.
[13]SINYUK M, MULKEARNS-HUBERT EE, REIZES O,et al. Cancer connectors:connexins, gap junctions, and communication[J]. Front Oncol, 2018, 8:646. doi:10.3389/fonc. 2018. 00646.
[14]吴以岭.气络-NEI网络相关性探析[J].中医杂志，2005,46(10):723-726.
[15]李红蓉，魏聪，贾振华，等.气络学说指导抗衰老研究[J].中国实验方剂学杂志，2022,28(1):7-15.
[16]PAVLIDES S, WHITAKER-MENEZES D, CASTELLOCROS R, et al. The reverse Warburg effect:aerobic glycolysis in cancer associated fibroblasts and the tumor stroma[J]. Cell Cycle, 2009, 8(23):3984-4001.
[17]JONES JC, BODENSTINE TM. Connexins and glucose metabolism in cancer[J]. Int J Mol Sci, 2022, 23(17):10172.
[18]CALVO F, EGE N, GRANDE-GARCIA A, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancerassociated fibroblasts[J]. Nat Cell Biol, 2013, 15(6):637-646.
[19]王宁，张艳，张珉，等.缝隙连接蛋白43对成纤维细胞中Ⅰ型胶原蛋白的调节作用[J].中国老年学杂志，2019,39(10):2441-2445.
[20]叶茜文，邹玺.基于癌毒病机理论探讨连接蛋白在肿瘤微环境中作用[J].中医药临床杂志，2024,36(5):811-816.
[21]何洁茹，邓金凤.痰湿体质和酸性体质的相关性思考[J].江西中医学院学报，2010,22(2):15-17.
[22]张彩霞，江滨，张亚杰，等.间隙连接蛋白Cx43在肿瘤发生发展中作用[J].辽宁中医药大学学报，2017,19(1):147-151.
[23]THURINGER D, BERTHENET K, CRONIER L, et al.Primary tumor-and metastasis-derived colon cancer cells differently modulate connexin expression and function in human capillary endothelial cells[J]. Oncotarget, 2015,6(30):28800-28815.
[24]李奕，庞博，花宝金，等.基于络病理论探讨恶性肿瘤的病机[J].中医杂志，2022,63(15):1427-1430.
[25]王永炎，常富业，杨宝琴.病络与络病对比研究[J].北京中医药大学学报，2005,28(3):1-6.
[26]张建斌，王玲玲.对《内经》中病理性络脉的分析[J].江苏中医，2001,22(10):43-45.
[27]SOLAN JL, LAMPE PD. Connexin43 phosphorylation:structural changes and biological effects[J]. Biochem J,2009, 419(2):261-272.
[28]GOULD VE, MOSQUERA JM, LEYKAUF K, et al.The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries[J]. Hum Pathol, 2005, 36(5):536-545.
[29]MITRA S, ANNAMALAI L, CHAKRABORTY S, et al.Androgen-regulated formation and degradation of gap junctions in androgen-responsive human prostate cancer cells[J]. Mol Biol Cell, 2006, 17(12):5400-5416.
[30]赵仲雪，庞立健，滑振，等.“络虚不荣”贯穿肺纤维化病程始终理论探析[J].中医药导报，2016,22(4):9-11.
[31]王一然，李晶.从络病理论认识肿瘤新生血管[J].中医学报，2023,38(3):525-529.
[32]陈珏，吴苏，廖蜀宁，等.络瘀生癌毒与恶性肿瘤[J].中华中医药杂志，2024,39(4):2062-2065.
[33]周静.丹参酮ⅡA对自杀基因旁观者效应增效作用及机制研究[D].广州：广州中医药大学，2010.
[34]姚庆华，郭勇，杨维鸿，等.复方藤梨根制剂调节PG细胞间隙连接蛋白Cx43基因表达水平的研究[J].中国现代应用药学，2006,23(6):435-438.
[35]戴朝明，靳松.大黄?虫丸对原发性肝癌瘀血阻络型患者AFP-L3、VEGF、TGF-β1及免疫功能的影响[J].浙江中医杂志，2021,56(5):313-314.
[36]普振清，王桂彬，张辰阳，等.基于“络脉伏风”探讨肿瘤血管生成的病机与治疗策略[J].中医杂志，2025,66(2):139-144.
[37]SONG Y, HUANG Q, PU Q, et al. Gastrodin liposomes block crosstalk between astrocytes and glioma cells via downregulating Cx43 to improve antiglioblastoma efficacy of temozolomide[J]. Bioconjug Chem, 2024, 35(9):1380-1390.
[38]郝淑兰，宁博彪，张晓文.王晞星治疗脑肿瘤角药经验撷菁[J].中国民间疗法，2020,28(11):37-40.
[39]吴以岭，赵珊珊，魏聪，等.试论气络病变治疗十法[J].中国实验方剂学杂志，2018,24(9):1-8.
[40]赵岩，杨丹，于珊珊.黄芪甲苷对慢性心力衰竭大鼠心肌细胞凋亡及P-Cx43表达水平的影响[J].临床和实验医学杂志，2018,17(20):2143-2147.
基本信息:
DOI：10.13288/j.11-2166/r.2025.13.002
中图分类号:R273
引用信息:
[1]熊宏泰,宋英,杜炎远等.“络息成积”与缝隙连接细胞间通讯异常的相关性及其在肿瘤防治中的应用[J].中医杂志,2025,66(13):1311-1316.DOI:10.13288/j.11-2166/r.2025.13.002.
基金信息:
国家自然科学基金（82174463）; 中央高水平中医医院临床研究和成果转化能力提升项目（HLCMHPP2023085）